Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Allergy Therapeutics (AGYTF) Stock-Based Compensation data is not available for the most recently reported fiscal quarter, ending 2024-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$42.17M |
|
$50.34M |
|
$59.91M |
|
$81.64M |
|
$25.87M |
|
$36.36M |
|
$51.10M |
|
$76.97M |
|
$4.67M |
|
$-1.23M |
|
$4.67M |
|
-- |
|
| Cash Flow Statement Financials | |
$-40.48M |
|
$-1.51M |
|
$39.58M |
|
$18.70M |
|
$16.27M |
|
$-2.43M |
|
|
Stock-Based Compensation |
-- |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|